APLT INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Class Action Lawsuit Details - Purchasers or acquirers of Applied Therapeutics securities between January 3, 2024, and December 2, 2024, have until February 18, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1] - The lawsuit charges Applied Therapeutics and certain top executives with violations of the Securities Exchange Act of 1934 [1] - The lead plaintiff process allows any investor who purchased or acquired Applied Therapeutics securities during the Class Period to seek appointment as lead plaintiff, with the lead plaintiff acting on behalf of all other class members [2] Robbins Geller Law Firm - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having secured the most monetary relief for investors in six out of the last ten years [3] - The firm recovered $6.6 billion for investors in securities-related class action cases, over $2.2 billion more than any other law firm in the last four years [3] - Robbins Geller has 200 lawyers in 10 offices and has obtained many of the largest securities class action recoveries in history, including the largest ever at $7.2 billion [3] Applied Therapeutics Allegations - Applied Therapeutics is a clinical-stage biopharmaceutical company developing novel drug candidates for rare diseases [5] - The company submitted a New Drug Application (NDA) to the FDA for govorestat for the treatment of Classic Galactosemia on January 3, 2024 [5] - The lawsuit alleges that Applied Therapeutics made false and/or misleading statements and failed to disclose that it was not adhering to trial protocol and good clinical practices, creating a severe risk that trial data would be rejected by the FDA [6] - On November 27, 2024, the FDA issued a Complete Response Letter for the NDA, indicating it could not approve the application in its current form due to deficiencies in the clinical application, causing the stock price to fall more than 80% over three trading sessions [6] - On December 2, 2024, Applied Therapeutics disclosed receiving a warning from the FDA regarding issues related to electronic data capture and a dosing error, causing the stock price to fall more than 26% over three trading sessions [6]